BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19039306)

  • 1. Renal manifestations in Fabry disease and therapeutic options.
    Torra R
    Kidney Int Suppl; 2008 Dec; (111):S29-32. PubMed ID: 19039306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
    Tahir H; Jackson LL; Warnock DG
    J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
    Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
    Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy and Fabry nephropathy.
    Warnock DG; Daina E; Remuzzi G; West M
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
    Desnick RJ; Banikazemi M; Wasserstein M
    Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
    Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
    J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy.
    Torra R; Algaba F; Ars E; Santin S; Fernández-Llama P; Ballarin J
    Clin Nephrol; 2008 Jun; 69(6):445-9. PubMed ID: 18538121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?
    Ozer H; Baloglu I; Topkac A; Ozturk Y; Yonet F; Daglı F; Kilinc İ; Turkmen K
    Nefrologia (Engl Ed); 2024; 44(2):217-223. PubMed ID: 37179210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabry nephropathy and the case for adjunctive renal therapy.
    Wanner C; Breunig F
    J Am Soc Nephrol; 2007 Sep; 18(9):2426-8. PubMed ID: 17699807
    [No Abstract]   [Full Text] [Related]  

  • 10. Renal complications of Fabry disease.
    Basic-Jukic N; Kes P; Coric M; Basic-Kes V
    Curr Pharm Des; 2013; 19(33):6046-50. PubMed ID: 23448456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
    Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
    G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
    Chen Z; Yin B; Jiao J; Ye T
    BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal complications of Fabry disease in children.
    Najafian B; Mauer M; Hopkin RJ; Svarstad E
    Pediatr Nephrol; 2013 May; 28(5):679-87. PubMed ID: 22898981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kidney in Fabry's disease.
    Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
    Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
    Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.
    Warnock DG; Thomas CP; Vujkovac B; Campbell RC; Charrow J; Laney DA; Jackson LL; Wilcox WR; Wanner C
    J Med Genet; 2015 Dec; 52(12):860-6. PubMed ID: 26490103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteinuria and its consequences in renal disease.
    Schieppati A; Remuzzi G
    Acta Paediatr Suppl; 2003 Dec; 92(443):9-13; discussion 5. PubMed ID: 14989459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Functional renal investigation in Fabry disease].
    Froissart M; Benistan K; Germain DP
    Presse Med; 2007 Mar; 36 Spec No 1():1S36-42. PubMed ID: 17546766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal pathological changes in Fabry disease.
    Sessa A; Meroni M; Battini G; Maglio A; Brambilla PL; Bertella M; Nebuloni M; Pallotti F; Giordano F; Bertagnolio B; Tosoni A
    J Inherit Metab Dis; 2001; 24 Suppl 2():66-70; discussion 65. PubMed ID: 11758681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.